Metformin Research & Listing Availability

How it works

Metformin is a small biguanide molecule (a dimer of guanidine units, structurally inspired by an alkaloid from Galega officinalis) that has been used clinically for diabetes since the 1950s in Europe and since 1994 in the United States. Its dominant clinical mechanism is suppression of hepatic gluconeogenesis: metformin accumulates in hepatocytes (positively charged at physiologic pH; concentrated by organic cation transporters), partially inhibits mitochondrial complex I, lowers cellular ATP, and raises the AMP:ATP ratio.[3] The elevated AMP activates AMP-activated protein kinase (AMPK), the central cellular energy sensor; AMPK then reduces gluconeogenic gene expression and improves peripheral insulin sensitivity. Subsequent mechanistic work has identified additional pathways: direct inhibition of mitochondrial glycerophosphate dehydrogenase (an AMPK-independent contributor to gluconeogenesis suppression),[8] effects on the gut microbiome (most circulating metformin is concentrated in the gut), intestinal AMPK signalling, mTOR pathway modulation, and effects on the lysosomal v-ATPase. The longevity hypothesis builds on the AMPK and mTOR effects, which are also produced by caloric restriction and rapamycin — two interventions with established preclinical lifespan-extending activity.

Active research areas

• Type 2 diabetes (UKPDS and first-line status)
  UKPDS 34 established that intensive glucose control with metformin in newly-diagnosed overweight T2D reduced any-diabetes-related-endpoint, diabetes-related death, and all-cause mortality versus conventional therapy; this remains the foundational evidence for metformin as first-line T2D pharmacotherapy in all major guidelines.[1] The Diabetes Prevention Program separately established metformin's role in preventing progression from prediabetes to T2D, with a 31% reduction in incident T2D over 2.8 years.[6]
• TAME trial (longevity hypothesis)
  The Targeting Aging with Metformin (TAME) trial, proposed by Nir Barzilai and colleagues, is a Phase 3-style 3,000-person, 6-year placebo-controlled trial in older adults without diabetes designed to test whether metformin delays a composite endpoint of age-related disease (cancer, cardiovascular disease, cognitive impairment, mortality).[4] TAME would be the first regulatory-grade test of an anti-aging hypothesis in humans; funding and trial start have been ongoing through 2024–2025.
• Healthspan-supportive mechanisms (preclinical and observational)
  Preclinical work in C. elegans, mice, and rats has reported lifespan and healthspan extension with metformin, with mechanisms variously attributed to AMPK activation, mTOR suppression, mitochondrial-stress responses, and gut-microbiome effects.[7] Observational human work — including the Bannister et al. mortality analysis — supports a mortality benefit beyond what would be expected from glycemic improvement alone.[2]
• Cancer prevention (observational and small trials)
  A large observational literature has reported associations between metformin use and reduced cancer incidence in T2D, particularly for colorectal, breast, prostate, and liver cancers. Randomised trials in small populations (MA.32 in breast cancer, METAL in colorectal adenoma) have produced mixed results, and the literature is heavily affected by immortal-time bias and other observational-study limitations.
• Exercise adaptation interactions (MASTERS, MILES, MERIT)
  A separate trial program has tested whether metformin blunts the mitochondrial and cardiorespiratory adaptations to aerobic exercise in older adults. MASTERS reported that metformin reduced exercise-induced VO2max improvement and skeletal-muscle mitochondrial respiration in older non-diabetic adults — a finding that complicates the longevity case for combining metformin with exercise programs.[5]